Guest guest Posted November 15, 2005 Report Share Posted November 15, 2005 Hi all, As usual, bumped me off the list so I missed some discussions. I found some information that I thought you might find interesting about expected sales of Gleevec for the next few years. Make no mistake that Novartis is going to do what it can to reap big rewards from this drug. This is from a listserv about medical costs/advertising. ~ G. www.cmlsupport.com ==================== Gleevec has long-term growth potential. Growth will be fueled by prolongation of patient-survival time, maintenance therapy, and greater number of prescriptions per patient. Merrill Lynch & Co. (ml.com) predicts steadily climbing sales of Gleevec. In 2004, the product is expected to generate $1.57 billion. In 2005, sales are predicted to grow to $1.84 billion. Sales are projected to be $2.16 billion in 2006, $2.46 billion in 2007, and $2.73 billion in 2008 In refining Gleevec's use in treating chronic myeloid leukemia, Novartis is continuing to make more discoveries that may increase product sales. One of those discoveries is that the product is more effective at higher doses. ======================= Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.